Dhruva SS - Search Results

1

Feasibility of capturing real-world data from health information technology systems at multiple centers to assess cardiac ablation device outcomes: A fit-for-purpose informatics analysis report.

Jiang G, Dhruva SS, Chen J, Schulz WL, Doshi AA, Noseworthy PA, Zhang S, Yu Y, Patrick Young H, Brandt E, Ervin KR, Shah ND, Ross JS, Coplan P, Drozda JP. Jiang G, et al. Among authors: dhruva ss. J Am Med Inform Assoc. 2021 Sep 18;28(10):2241-2250. doi: 10.1093/jamia/ocab117. J Am Med Inform Assoc. 2021. PMID: 34313748 Free PMC article.

2

Revisiting Essure--Toward Safe and Effective Sterilization.

Dhruva SS, Ross JS, Gariepy AM. Dhruva SS, et al. N Engl J Med. 2015 Oct 8;373(15):e17. doi: 10.1056/NEJMp1510514. Epub 2015 Sep 23. N Engl J Med. 2015. PMID: 26397951 No abstract available.

3

Medicare Formulary Changes After the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline.

Dhruva SS, Desai NR, Karaca-Mandic P, Shah ND, Ross JS. Dhruva SS, et al. J Am Coll Cardiol. 2017 Jan 17;69(2):244-246. doi: 10.1016/j.jacc.2016.10.053. J Am Coll Cardiol. 2017. PMID: 28081832 Free article. No abstract available.

4

Inclusion of Demographic-Specific Information in Studies Supporting US Food & Drug Administration Approval of High-Risk Medical Devices.

Dhruva SS, Mazure CM, Ross JS, Redberg RF. Dhruva SS, et al. JAMA Intern Med. 2017 Sep 1;177(9):1390-1391. doi: 10.1001/jamainternmed.2017.3148. JAMA Intern Med. 2017. PMID: 28738116 Free PMC article.

5

The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States.

Gupta R, Dhruva SS, Fox ER, Ross JS. Gupta R, et al. Among authors: dhruva ss. J Manag Care Spec Pharm. 2017 Oct;23(10):1066-1076. doi: 10.18553/jmcp.2017.23.10.1066. J Manag Care Spec Pharm. 2017. PMID: 28944731 Free PMC article.

6

Medicare Formulary Coverage Restrictions for Prescription Opioids, 2006 to 2015.

Samuels EA, Ross JS, Dhruva SS. Samuels EA, et al. Among authors: dhruva ss. Ann Intern Med. 2017 Dec 19;167(12):895-896. doi: 10.7326/M17-1823. Epub 2017 Oct 10. Ann Intern Med. 2017. PMID: 29052693 No abstract available.

7

Association between FDA black box warnings and Medicare formulary coverage changes.

Dhruva SS, Karaca-Mandic P, Shah ND, Shaw DL, Ross JS. Dhruva SS, et al. Am J Manag Care. 2017 Sep 1;23(9):e310-e315. Am J Manag Care. 2017. PMID: 29087169 Free article.

8

New and incremental FDA black box warnings from 2008 to 2015.

Solotke MT, Dhruva SS, Downing NS, Shah ND, Ross JS. Solotke MT, et al. Among authors: dhruva ss. Expert Opin Drug Saf. 2018 Feb;17(2):117-123. doi: 10.1080/14740338.2018.1415323. Epub 2017 Dec 17. Expert Opin Drug Saf. 2018. PMID: 29215916 Free PMC article.

9

Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015.

Egilman AC, Wallach JD, Ross JS, Dhruva SS. Egilman AC, et al. Among authors: dhruva ss. JAMA Intern Med. 2018 Apr 1;178(4):567-569. doi: 10.1001/jamainternmed.2017.8016. JAMA Intern Med. 2018. PMID: 29340562 Free PMC article.

10

Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis.

Wallach JD, Egilman AC, Dhruva SS, McCarthy ME, Miller JE, Woloshin S, Schwartz LM, Ross JS. Wallach JD, et al. Among authors: dhruva ss. BMJ. 2018 May 24;361:k2031. doi: 10.1136/bmj.k2031. BMJ. 2018. PMID: 29794072 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

197 results

Search Page